vs
Side-by-side financial comparison of Maison Solutions Inc. (MSS) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Maison Solutions Inc. is the larger business by last-quarter revenue ($27.6M vs $20.4M, roughly 1.4× Sight Sciences, Inc.). Maison Solutions Inc. runs the higher net margin — -18.0% vs -20.4%, a 2.4% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -10.9%). Over the past eight quarters, Maison Solutions Inc.'s revenue compounded faster (42.5% CAGR vs 2.9%).
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
MSS vs SGHT — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $20.4M |
| Net Profit | $-5.0M | $-4.2M |
| Gross Margin | 23.4% | 87.3% |
| Operating Margin | -4.9% | -18.0% |
| Net Margin | -18.0% | -20.4% |
| Revenue YoY | -10.9% | 6.9% |
| Net Profit YoY | -1840.5% | 64.9% |
| EPS (diluted) | $-0.23 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.6M | $20.4M | ||
| Q3 25 | $27.2M | $19.9M | ||
| Q2 25 | $34.4M | $19.6M | ||
| Q1 25 | $32.3M | $17.5M | ||
| Q4 24 | $29.4M | $19.1M | ||
| Q3 24 | $28.2M | $20.2M | ||
| Q2 24 | $16.9M | $21.4M | ||
| Q1 24 | $13.6M | $19.3M |
| Q4 25 | $-5.0M | $-4.2M | ||
| Q3 25 | $-1.5M | $-8.2M | ||
| Q2 25 | $-287.4K | $-11.9M | ||
| Q1 25 | $1.0M | $-14.2M | ||
| Q4 24 | $-256.0K | $-11.8M | ||
| Q3 24 | $700.9K | $-11.1M | ||
| Q2 24 | $-2.8M | $-12.3M | ||
| Q1 24 | $-549.0K | $-16.3M |
| Q4 25 | 23.4% | 87.3% | ||
| Q3 25 | 24.1% | 86.4% | ||
| Q2 25 | 9.5% | 84.8% | ||
| Q1 25 | 21.8% | 86.2% | ||
| Q4 24 | 26.9% | 86.8% | ||
| Q3 24 | 28.9% | 83.9% | ||
| Q2 24 | 13.0% | 85.8% | ||
| Q1 24 | 23.4% | 85.5% |
| Q4 25 | -4.9% | -18.0% | ||
| Q3 25 | 0.7% | -39.7% | ||
| Q2 25 | -15.9% | -59.6% | ||
| Q1 25 | 3.7% | -79.2% | ||
| Q4 24 | 3.2% | -62.5% | ||
| Q3 24 | 7.3% | -55.7% | ||
| Q2 24 | -14.4% | -59.2% | ||
| Q1 24 | -2.3% | -76.4% |
| Q4 25 | -18.0% | -20.4% | ||
| Q3 25 | -5.7% | -41.0% | ||
| Q2 25 | -0.8% | -61.0% | ||
| Q1 25 | 3.1% | -80.8% | ||
| Q4 24 | -0.9% | -62.1% | ||
| Q3 24 | 2.5% | -54.9% | ||
| Q2 24 | -16.4% | -57.7% | ||
| Q1 24 | -4.0% | -84.4% |
| Q4 25 | $-0.23 | $-0.07 | ||
| Q3 25 | $-0.08 | $-0.16 | ||
| Q2 25 | $-0.02 | $-0.23 | ||
| Q1 25 | $0.06 | $-0.28 | ||
| Q4 24 | $-0.01 | $-0.23 | ||
| Q3 24 | $0.04 | $-0.22 | ||
| Q2 24 | $-0.16 | $-0.25 | ||
| Q1 24 | $-0.03 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | $2.6M | $42.4M |
| Stockholders' EquityBook value | $11.6M | $63.9M |
| Total Assets | $75.4M | $115.3M |
| Debt / EquityLower = less leverage | 0.22× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.0M | ||
| Q3 25 | $1.1M | $92.4M | ||
| Q2 25 | $775.4K | $101.5M | ||
| Q1 25 | $445.4K | $108.8M | ||
| Q4 24 | $355.7K | $120.4M | ||
| Q3 24 | $588.9K | $118.6M | ||
| Q2 24 | $2.1M | $118.2M | ||
| Q1 24 | $9.4M | $127.3M |
| Q4 25 | $2.6M | $42.4M | ||
| Q3 25 | $2.6M | $42.4M | ||
| Q2 25 | $2.6M | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | $2.5M | $37.1M | ||
| Q2 24 | $2.6M | $35.0M | ||
| Q1 24 | $2.6M | $35.0M |
| Q4 25 | $11.6M | $63.9M | ||
| Q3 25 | $10.1M | $64.3M | ||
| Q2 25 | $11.7M | $70.0M | ||
| Q1 25 | $12.0M | $77.6M | ||
| Q4 24 | $10.9M | $87.5M | ||
| Q3 24 | $11.2M | $95.0M | ||
| Q2 24 | $10.5M | $101.6M | ||
| Q1 24 | $13.3M | $109.2M |
| Q4 25 | $75.4M | $115.3M | ||
| Q3 25 | $73.3M | $116.3M | ||
| Q2 25 | $77.4M | $122.0M | ||
| Q1 25 | $82.7M | $129.7M | ||
| Q4 24 | $82.7M | $142.8M | ||
| Q3 24 | $82.1M | $143.6M | ||
| Q2 24 | $82.4M | $149.7M | ||
| Q1 24 | $44.2M | $155.6M |
| Q4 25 | 0.22× | 0.66× | ||
| Q3 25 | 0.26× | 0.66× | ||
| Q2 25 | 0.22× | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | 0.23× | 0.39× | ||
| Q2 24 | 0.24× | 0.34× | ||
| Q1 24 | 0.19× | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-1.8M | ||
| Q3 25 | $1.1M | $-8.7M | ||
| Q2 25 | $-1.6M | $-7.5M | ||
| Q1 25 | $1.7M | $-11.6M | ||
| Q4 24 | $1.1M | $-3.5M | ||
| Q3 24 | $3.6M | $362.0K | ||
| Q2 24 | $-2.6M | $-9.5M | ||
| Q1 24 | $-1.4M | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.66× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.12× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
